Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS)
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study
Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes
Objective/background: Relapse is the most common cause of treatment failure after allogeneic hematopoietic cell transplantation (alloHCT). No standard of care exists, and a wide range of treatments are used for post-alloHCT relapse. In the recent era, several novel therapies including targeted agents are available for acute lymphocytic leukemia (ALL),
Current and emerging strategies for management of myelodysplastic syndromes
TP53 Modifier Impresses in Early MDS/AML Study
A drug that targets a common mutation in
Azacitidine Maintenance Fails to Improve Post-Transplant Outcomes in High-Risk AML and MDS
Targeted therapy venetoclax improving acute myeloid leukemia treatment options
Targeted therapies are designed to work against specific vulnerabilities in a cancer cell.
The targeted therapy drug venetoclax is designed to block the function of the B-cell lymphoma-2 (Bcl-2) protein, which normally works to prevent cell death.
Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome
Key Points
Recipient telomere length is independently associated with overall survival and NRM after transplantation for MDS.